Alcobra Ltd. (ADHD) Lowered to “Neutral” at Piper Jaffray Cos.
Several other equities research analysts also recently commented on the stock. WBB Securities downgraded shares of Alcobra from a hold rating to a sell rating and reduced their target price for the company from $5.00 to $4.00 in a research note on Monday, September 12th. Barclays PLC began coverage on shares of Alcobra in a research report on Monday, August 1st. They set an equal weight rating and a $8.00 price target on the stock. Cantor Fitzgerald reiterated a buy rating and set a $16.00 price target on shares of Alcobra in a research report on Thursday. Zacks Investment Research downgraded shares of Alcobra from a hold rating to a sell rating in a research report on Monday, July 18th. Finally, Oppenheimer Holdings Inc. downgraded shares of Alcobra from an outperform rating to a market perform rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $8.34.
Alcobra (NASDAQ:ADHD) traded down 1.59% during mid-day trading on Thursday, hitting $2.47. 708,233 shares of the company were exchanged. The company’s market cap is $68.08 million. Alcobra has a 12-month low of $1.95 and a 12-month high of $8.78. The stock’s 50 day moving average is $4.76 and its 200-day moving average is $4.52.
Alcobra (NASDAQ:ADHD) last issued its earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. Equities research analysts predict that Alcobra will post ($0.96) EPS for the current year.
Institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. raised its position in shares of Alcobra by 28.2% in the first quarter. Franklin Resources Inc. now owns 3,652,931 shares of the company’s stock valued at $13,845,000 after buying an additional 804,350 shares in the last quarter. BlackRock Fund Advisors increased its position in Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock worth $1,344,000 after buying an additional 36,218 shares during the period. Jefferies Group LLC purchased a new position in Alcobra during the second quarter worth $533,000. VHCP Management II LLC increased its position in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the period. Finally, VHCP Management LLC increased its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the period. Institutional investors and hedge funds own 73.69% of the company’s stock.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.